U.S. Biotech Industry Analysis

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 10 Jul 2026	US$1.5t	US$169.9b	-US$12,047,484,444.75	17.5x	-121.8x	8.6x
Sun, 07 Jun 2026	US$1.3t	US$170.0b	-US$12,160,280,783.82	16.6x	-104.3x	7.5x
Tue, 05 May 2026	US$1.3t	US$167.5b	-US$11,616,741,742.25	17.2x	-108.9x	7.6x
Thu, 02 Apr 2026	US$1.3t	US$166.1b	-US$11,596,621,749.18	14.9x	-110.9x	7.7x
Sat, 28 Feb 2026	US$1.3t	US$169.4b	-US$13,319,467,287.61	21.7x	-101.1x	7.9x
Mon, 26 Jan 2026	US$1.3t	US$163.5b	-US$15,173,296,321.83	19.9x	-83.6x	7.8x
Wed, 24 Dec 2025	US$1.2t	US$163.6b	-US$15,779,683,760.87	21.6x	-78.8x	7.6x
Fri, 21 Nov 2025	US$1.2t	US$163.8b	-US$16,219,175,263.21	17.4x	-73.7x	7.3x
Sun, 19 Oct 2025	US$1.2t	US$163.4b	-US$18,206,489,780.58	16.4x	-64.1x	7.1x
Tue, 16 Sep 2025	US$1.1t	US$163.6b	-US$18,378,517,336.68	15.8x	-58.3x	6.6x
Thu, 14 Aug 2025	US$1.0t	US$163.2b	-US$14,658,010,083.94	15.6x	-70.7x	6.4x
Sat, 12 Jul 2025	US$985.4b	US$155.8b	-US$23,408,172,286.86	18.5x	-42.1x	6.3x
Mon, 09 Jun 2025	US$951.3b	US$155.9b	-US$23,930,730,032.61	16.8x	-39.8x	6.1x
Wed, 07 May 2025	US$949.3b	US$154.1b	-US$25,408,936,426.34	18.3x	-37.4x	6.2x
Fri, 04 Apr 2025	US$791.2b	US$118.6b	-US$37,117,653,368.22	21.5x	-21.3x	6.7x
Sun, 02 Mar 2025	US$850.7b	US$118.9b	-US$37,265,127,499.97	17x	-22.8x	7.2x
Tue, 28 Jan 2025	US$983.3b	US$149.5b	-US$26,320,225,889.85	17.1x	-37.4x	6.6x
Thu, 26 Dec 2024	US$990.4b	US$149.9b	-US$26,369,148,329.00	16x	-37.6x	6.6x
Sat, 23 Nov 2024	US$1.0t	US$150.0b	-US$26,559,949,256.44	17x	-37.7x	6.7x
Mon, 21 Oct 2024	US$908.0b	US$113.1b	-US$35,950,283,773.02	21.7x	-25.3x	8x
Wed, 18 Sep 2024	US$929.9b	US$113.2b	-US$35,966,527,614.94	22.9x	-25.9x	8.2x
Fri, 16 Aug 2024	US$870.9b	US$113.2b	-US$36,254,285,538.64	22.2x	-24x	7.7x
Sun, 14 Jul 2024	US$1.2t	US$164.5b	-US$28,119,714,352.84	29.4x	-42.5x	7.3x
Tue, 11 Jun 2024	US$1.2t	US$164.5b	-US$26,797,092,425.07	28.1x	-43.3x	7.1x
Thu, 09 May 2024	US$1.1t	US$164.6b	-US$26,520,766,232.38	24.3x	-42.5x	6.8x
Sat, 06 Apr 2024	US$1.1t	US$164.4b	-US$23,433,178,577.03	25x	-47.8x	6.8x
Mon, 04 Mar 2024	US$1.2t	US$167.9b	-US$21,330,880,627.75	15.9x	-56.4x	7.2x
Wed, 31 Jan 2024	US$1.4t	US$204.7b	-US$22,654,596,727.00	17.8x	-63.8x	7.1x
Fri, 29 Dec 2023	US$1.4t	US$204.9b	-US$22,192,805,164.00	19.9x	-62.8x	6.8x
Sun, 26 Nov 2023	US$1.2t	US$204.8b	-US$22,013,452,568.00	18.6x	-55.7x	6x
Tue, 24 Oct 2023	US$1.2t	US$207.5b	-US$13,040,981,709.00	16.2x	-93x	5.8x
Thu, 21 Sep 2023	US$1.3t	US$207.5b	-US$12,879,934,249.00	16.5x	-99.1x	6.1x
Sat, 19 Aug 2023	US$1.3t	US$207.6b	-US$12,299,327,844.00	17.4x	-102.8x	6.1x
Mon, 17 Jul 2023	US$1.1t	US$186.7b	-US$15,968,283,125.00	12.9x	-71.1x	6.1x

Current Industry PE

Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.

The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 8.6x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have improved over the last three years.
Meanwhile revenues for these companies have declined 3.1% per year.
This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?


US Market	-0.43%
Healthcare	1.81%
Biotech	3.41%
Biotech	3.41%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
GILD Gilead Sciences	US$134.84	2.7% +US$4.4b	17.7%	PE18.2x
BBIO BridgeBio Pharma	US$90.17	16.8% +US$2.5b	94.9%	PS30.5x
INSM Insmed	US$118.26	6.0% +US$1.4b	22.3%	PS31.3x
REGN Regeneron Pharmaceuticals	US$667.95	2.1% +US$1.4b	19.3%	PE15.4x
ROIV Roivant Sciences	US$36.81	4.8% +US$1.2b	218.2%	PS3205.4x

BridgeBio Pharma, Inc. announced that it expects to receive $1 billion in funding from Chinotto Investments, LLC, HCRX Investments HoldCo, L.P. and other investors.

BridgeBio Pharma, Inc. announced that it has entered into an Investment Agreement providing for the issuance and sale by the Company to the Purchasers of shares of the 1,000,000 Company’s Series A Senior Cumulative Convertible Redeemable Participating Preferred Stock at a par value $0.001 per share at an issue price of $1,000 per share for gross proceeds of $1,000,000,000 on July 1, 2026. On the same day the company issued 933,900 Series A Cumulative Convertible Participating Preferred Stock at an issue price of $1000 for gross proceeds of $933,900,000 in its first tranche. In addition subject to approval by the Company’s Board of Directors, the company will issue remaining preferred shares for gross proceeds $66,100,000 from time to time in such amounts as the Sixth Street Purchaser may determine. The transaction includes participation from Chinotto Investments, LLC (the “Sixth Street Purchaser”) for 800,000 shares for proceeds of $800,000,000 as a lead investor, HCRx Investments HoldCo, L.P. (the “HCR Purchaser”) for 133,900 shares for proceeds of $133,900,000 and Chinotto Investments, LLC (Sixth Street Purchaser) or its affiliates for $66,100,000. Holders of the Preferred Stock have the right, at any time and from time to time, to convert their shares of Preferred Stock into shares of Common Stock at the then-effective conversion price, which is initially $137.79 per share and, on and after the fifth anniversary of the Original Issuance Date, $153.10 per share, in each case subject to customary anti-dilution adjustments. The Purchased Shares are initially convertible for an aggregate of 6,777,705 shares of Common Stock. The Preferred Stock ranks senior to the Common Stock and each other class or series of the Company’s equity securities with respect to the payment of dividends and rights on liquidation, dissolution or winding up. Holders of the Preferred Stock are entitled to dividends that accrue and accumulate daily, whether or not declared, at a rate of 7.00% per annum on the Accumulated Amount of such shares, payable quarterly in arrears and, at the Company’s option, either in cash or by compounding and adding to the Accumulated Amount. The preferred stock is Permanent equity with no scheduled maturity and no redemption at the holder’s option. BridgeBio may redeem the preferred stock for cash or, in certain circumstances, convert it into common stock, in each case on the terms set forth in the definitive agreements. If required by the applicable rules of The Nasdaq Stock Market LLC (“Nasdaq”) to permit the conversion of all shares of Preferred Stock into Common Stock without giving effect to the limitations on conversion set forth in the Certificate of Designations, the Company has agreed to seek the approval of its stockholders (the “Requisite Stockholder Approval”) at its 2027 annual meeting of stockholders or, if such meeting is not held by June 30, 2027, at a special meeting of stockholders to be held no later than June 30, 2027. The issuance and sale of the Preferred Stock was made in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof. Any shares of Common Stock that may be issued upon conversion of the Preferred Stock will be issued in reliance upon Section 3(a)(9) of the Securities Act. Each Purchaser represented to the Company that it is an “accredited investor” as defined in Rule 501 of Regulation D under the Securities Act.

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Chief Medical Officer exercised options and sold US$1.0m worth of stock

Ionis Pharmaceuticals Provides Update on CARDIO-TTRansform Phase 3 Trial of Eplontersen in Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

Moderna, Inc. Announces Board and Committee Changes, Effective July 8, 2026

Amgen Recalls Corlanor and Sensipar Across US Over Quality and Compliance Concerns

VRTX: Rich Crinetics Deal Will Weigh On Future Risk Reward Profile

Regeneron Expects $127 Million R&D Charge in Q2 2026 to Affect Earnings

Roivant Sciences Set to Receive Major Cash Inflow From $2.25 Billion Moderna Settlement

BIIB: Alzheimer’s Trial Uncertainty Will Likely Undermine Recent Acquisition Optimism

Upcoming dividend of US$1.73 per share

ImmunityBio: A Long-Term Bull Case Worth Watching

TGTX: Subcutaneous Autoimmune Franchise Is Expected To Drive Future Re Rating

FDA Approves Trodelvy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

BNTX: Oncology Pipeline Data Cycle Will Drive Future Upside Potential

BridgeBio Pharma, Inc. announced that it expects to receive $1 billion in funding from Chinotto Investments, LLC, HCRX Investments HoldCo, L.P. and other investors.

Spyre Therapeutics, Inc.(NasdaqGS:SYRE) dropped from Russell 2000 Value Benchmark

XENE: Phase 3 Success And Mixed Street Views Will Shape Next Chapter